Last update 31 Aug 2025

CNTX-6970

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CNTX 6970
Target
CCR2
Action
antagonists
Mechanism
CCR2 antagonists(C-C chemokine receptor type 2 antagonists)
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal Diseases
Active Indication
Osteoarthritis, Knee
Inactive Indication
Chronic PainInflammatory painNociceptive Pain+ [1]
Originator Organization
C.H. Boehringer Sohn AG & Co. KG
Active Organization
The Massachusetts General HospitalThe Massachusetts General Hospital
Inactive Organization
Centrexion Therapeutics Corp.Centrexion Therapeutics Corp.Boehringer Ingelheim GmbHBoehringer Ingelheim GmbHC.H. Boehringer Sohn AG & Co. KG
License Organization
Boehringer Ingelheim GmbHBoehringer Ingelheim GmbHCentrexion Therapeutics Corp.Centrexion Therapeutics Corp.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with CNTX-6970
NCT05025787
/ CompletedPhase 2IIT
EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.
NCT03787004
/ CompletedPhase 1
A Placebo-Controlled, Two-Part Study With Single Dose and Multiple Ascending Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects
100 Clinical Results associated with CNTX-6970
Login to view more data
100 Translational Medicine associated with CNTX-6970
Login to view more data
100 Patents (Medical) associated with CNTX-6970
Login to view more data
100 Deals associated with CNTX-6970
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteoarthritis, KneePhase 2
United States
The Massachusetts General HospitalThe Massachusetts General Hospital
25 Oct 2021
Inflammatory painPhase 2
United States
Boehringer Ingelheim GmbHBoehringer Ingelheim GmbH
27 Oct 2020
Chronic PainPhase 1
United States
Centrexion Therapeutics Corp.Centrexion Therapeutics Corp.
14 Aug 2017
Nociceptive PainPhase 1
United States
Centrexion Therapeutics Corp.Centrexion Therapeutics Corp.
14 Aug 2017
PainPhase 1-
C.H. Boehringer Sohn AG & Co. KG
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free